Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 3, 2008, Pages 209-216

  Saito, T ^a   Yoshioka, S ^a   Iinuma, Y ^a   Takakura, S ^a   Fujihara, N ^a   Ichinohe, T ^a   Ishikawa, T ^a   Uchiyama, T ^a   Ichiyama, S ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CANCER CHEMOTHERAPY; DRUG TOLERABILITY; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; FEMALE; GRAM POSITIVE COCCI; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIA; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 41049117964     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0428-8     Document Type: Article

References (23)

1. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer-is it justified? Clin Infect Dis 25:346-348
2. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1995) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795-805
3. Engels EA, Lau J, Barza M (1999) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179-87
4. Klastersky J (1996) Prevention of infection in neutropenic cancer patients. Curr Opin Oncol 8:270-278
5. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977-987
6. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988-998
7. van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN (2005) Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41:1372-1382
8. Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979-995
9. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087-1093
10. Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330: 1240-1241
11. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have receiving prophylactic norfloxacin. Clin Infect Dis 20:557-560
12. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681-687
13. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490-494
14. Baum HV, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28:278-281
15. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551-575
16. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
17. Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene LN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B, Talcott JA (2004) Fever and neutropania. J National Comprehensive Cancer Network 23:390-432
18. Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39(Suppl 1):S11-14
19. National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne
20. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128-140
21. National Cancer Institute (2006) Cancer therapy evaluation program: common terminology criteria for adverse events version 3.0 (CTC). http://ctep.cancer.gov/forms/
22. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051
23. Vincent AL, Price R, Field T, Greene JN, Sandin RL (2005) Addition of fluoroquinolone prophylaxis to a blood and marrow transplant unit reduces gram-negative infections. Cancer Control 12:203-206